Clinical Trials · NCT00829192
Phase II AK Study in Organ Transplant Patients
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Clinuvel Pharmaceuticals Limited
- Enrollment
- 200
- Start date
- Nov 2007
- Locations
- 12 sites, 7 countries
- Primary endpoint
- To determine the effect of afamelanotide (CUV1647) administered from slow release subcutaneous implants on the number of actinic keratoses (AKs) on the head, forearms and back of hands